Management and Treatment of Andersen-Tawil Syndrome (ATS)

Neurotherapeutics

Volumn 4, Issue 2, 2007, Pages 233-237

  Sansone, Valeria ^a   Tawil, Rabi ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b STRONG MEMORIAL HOSPITAL   (United States)

Author keywords

Andersen Tawil syndrome; ATS; KCNJ2; LQT7; management; therapy

Indexed keywords

ACETAZOLAMIDE; AMIODARONE; AMLODIPINE; ANILINE; AZIMILIDE; BEPRIDIL; DICLOFENAMIDE; DISOPYRAMIDE; DOFETILIDE; ERYTHROMYCIN; GREPAFLOXACIN; HALOPERIDOL; IBUTILIDE; INWARDLY RECTIFYING POTASSIUM CHANNEL; MOXIFLOXACIN; NIFEDIPINE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; POTASSIUM; POTASSIUM CHANNEL KIR2.1; PROCAINAMIDE; PROPRANOLOL; QUINIDINE; SOTALOL; SPIRONOLACTONE; TRIAMTERENE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANDERSEN SYNDROME; ARTICLE; CHANNEL GATING; CLINICAL FEATURE; GENE; HEART ARRHYTHMIA; HEART DEPOLARIZATION; HUMAN; KCNJ2 GENE; LONG QT SYNDROME; PERIODIC PARALYSIS; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN FUNCTION; QT PROLONGATION; SECOND MESSENGER; SLOW RELEASE FORMULATION; SYMPTOM;

ANDERSEN SYNDROME; ANIMALS; DISEASE MODELS, ANIMAL; HEART; HUMANS; MUSCLE, SKELETAL; MUTATION; POTASSIUM CHANNELS, INWARDLY RECTIFYING;

EID: 33947530651     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2007.01.005     Document Type: Article

References (27)

1. Andersen E.D., Krasilnikoff P.A., and Overvad H. Intermittent muscular weakness, extrasystoles, and multiple developmental abnormalities: a new syndrome?. Acta Pediatr Scand 60 (1971) 559-564
2. Tawil R., Ptacek L.J., Pavlakis S.G., et al. Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol 35 (1994) 326-330
3. Sansone V., Griggs R.C., Meola G., Ptacek L.J., Barohn R., Iannaccone S., Bryan W., Baker N., Janas S.J., Scott W., Ririe D., and Tawil R. Andersen's syndrome: a distinct periodic paralysis. Ann Neurol 42 (1997) 305-312
4. Canun S., Perez N., and Beirana L.G. Andersen syndrome autosomal dominant in three generations. Am J Med Genet 85 (1999) 147-156
5. Plaster N.M., Tawil R., Tristani-Firouzi M., et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 105 (2001) 511-519
6. Tristani-Firouzi M., Jensen J.L., Donaldson M.R., et al. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest 110 (2002) 381-388
7. Tester D.J., Arya P., Will M., et al. Genotypic heterogeneity and phenotypic mimicry among unrelated patients referred for catecholaminergic polymorphic ventricular tachycardia genetic testing. Heart Rhythm 3 (2006) 800-805
8. Andelfinger G., Tapper A.R., Welch R.C., Vanoye C.G., George Jr. A.L., and Benson D.W. KCNJ2 mutation results in Andersen syndrome with sex-specific cardiac and skeletal muscle phenotypes. Am J Hum Genet 71 (2002) 663-668
9. Davies N.P., Imbrici P., Fialho D., et al. Andersen-Tawil syndrome: new potassium channel mutations and possible phenotypic variation. Neurology 65 (2005) 1083-1089
10. Khan I.A. Long QT syndrome: diagnosis and management. Am Heart J 143 (2002) 7-14
11. Zhang L., Benson D.W., Tristani-Firouzi M., et al. Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype. Circulation 111 (2005) 2720-2726
12. Tsuboi M., and Antzelevitch C. Cellular basis for electrocardiographic and arrhythmic manifestations of Andersen-Tawil syndrome (LQT7). Heart Rhythm 3 (2006) 328-335
13. Schoonderwoerd B.A., Wiesfeld A.C., Wilde A.A., et al. A family with Andersen-Tawil syndrome and dilated cardiomyopathy. Heart Rhythm 3 (2006) 1346-1350
14. McManis P.G., Lambert E.H., and Daube J.R. The exercise test in periodic paralysis. Muscle Nerve 9 (1986) 704-710
15. Fournier E., Arzel M., Sternberg D., et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol 56 (2004) 650-661
16. Katz J.S., Wolfe G.I., Iannaccone S., Bryan W.W., and Barohn R.J. The exercise test in Andersen syndrome. Arch Neurol 56 (1999) 352-356
17. Jongsma H.J., and Wilders R. Channelopathies: Kir2.1 mutations jeopardize many cell functions. Curr Biol 11 (2001) R747-R750
18. Lopatin A.N., and Nicholas C.G. Inward rectifiers in the heart: an update on Ik1. J Mol Cell Cardiol 1 (2001) 625-638
19. Chen L., Kawano T., Bajic S., et al. A glutamate residue at the C-terminus regulates activity of inward rectifier K+ channels: implication for Andersen's syndrome. Proc Natl Acad Sci U S A 99 (2002) 8430-8435
20. Hosaka Y., Hanawa H., Washizuka T., et al. Function, subcellular localization and assembly of a novel mutation of KCNJ2 in Andersen's syndrome. J Mol Cell Cardiol 35 (2003) 409-415
21. Donaldson M.R., Jensen J.L., Tristani-Firouzi M., et al. PIP2 binding residues of Kir2.1 are common targets of mutations causing Andersen syndrome. Neurology 60 (2003) 1811-1816
22. Bendahhou S., Donaldson M.R., Plaster N.M., Tristani-Firouzi M., Fu Y.H., and Ptacek L.J. Defective potassium channel Kir2.1 trafficking underlies Andersen-Tawil syndrome. J Biol Chem 278 (2003) 51779-51785
23. Preisig-Muller R., Schlichthorl G., Goerge T., et al. Heteromerization of Kir2.x potassium channels contributes to the phenotype of Andersen's syndrome. Proc Natl Acad Sci U S A 99 (2002) 7774-7779
24. Donaldson M.R., Yoon G., Fu Y.H., and Ptacek L.J. Andersen-Tawil syndrome: a model of clinical variability, pleiotropy and genetic heterogeneity. Ann Med 36 (2004) 92-97
25. Yoon G., Quitania L., Kramer J.H., Fu Y.H., Miller B.L., and Ptacek L.J. Andersen-Tawil syndrome: definition of a neurocognitive phenotype. Neurology 66 (2006) 1703-1710
26. Guyatt G.H., Heyting A., Jaeschke R., Keller J., Adachi J.D., and Roberts R.S. N of 1 randomized trials for investigating new drugs. Control Clin Trials 11 (1990) 88-100
27. Tawil R., McDermott M.P., Brown Jr. R., et al., Working Group on Periodic Paralysis. Randomized trials of dichlorphenamide in the periodic paralyses. Ann Neurol 47 (2000) 46-53